Clinical Trial

Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease

Name: Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease — clinical trial record (NCT07118696)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: RIFAstrat

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

RIFAstrat is a Phase 3, double-blind, placebo-controlled, non-inferiority trial to compare the 6-month standard treatment for DS-TB with a 4-month optimised- rifampicin based regimen provided to individuals with limited disease severity.

Trial Details

NCT Number	NCT07118696
Lead Sponsor	Hamilton Health Sciences Corporation Collaborators: St George's, University of London, McMaster University
Conditions	Pulmonary TB
Enrollment	1,000 participants
Start Date	2026-02-01
Primary Completion	2029-01-31 (estimated)
Study Completion	2030-01-31 (estimated)
Updated on ClinicalTrials.gov	2025-08-12